KURA ONCOLOGY, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
KURA ONCOLOGY, INC. (KURA) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $8.10 thousand as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2020-11-05
- 2020-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $8.10K.
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $40.70K.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $0.00.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $39.00M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2020-09-30 | $8.10K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $40.70K 10-Q · filed 2020-08-06 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $39.00M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $55.10M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |